Ischemic cardiomyopathy.
The term "ischemic cardiomyopathy" was used initially to describe a clinical syndrome that was indistinguishable from primary congestive cardiomyopathy but due to severe, diffuse coronary artery disease. The term has been expanded to include the larger category of myocardial disease secondary to coronary artery disease. Using this expanded definition, we have discussed the varied clinical presentations of congestive ischemic cardiomyopathy and restrictive ischemic cardiomyopathy (stiff heart syndrome and right ventricular infarction), and how the effects of ischemia on left ventricular systolic and diastolic performance may cause these varied presentations. The prognosis of any ischemic cardiomyopathy is related primarily to the degree of ventricular dysfunction and the extent of coronary artery disease. Therapy is aimed at preventing or ameliorating myocardial ischemia and halting the progression of, or even reversing, the deterioration in myocardial function.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000631:Aminopyridines / Q000627:therapeutic use; D000676:Amrinone; D002302:Cardiac Output; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D002316:Cardiotonic Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000150:complications*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology*; D016027:Heart Transplantation; D006801:Humans; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000175:diagnosis; D005082:Physical Exertion; D011379:Prognosis; D013318:Stroke Volume; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000631:Aminopyridines; D002316:Cardiotonic Agents; D004071:Digitalis Glycosides; D004232:Diuretics; D014665:Vasodilator Agents; D000676:Amrinone